ArticleFrontiers in aging neuroscience2026
Cooling the burn: EMLA alone vs. paravertebral block plus EMLA for improving tolerability of 8% capsaicin patch application in thoracic postherpetic neuralgia-a retrospective cohort study.
Article in Frontiers in aging neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The 8% capsaicin patch (Qutenza®) is an effective localized treatment for postherpetic neuralgia (PHN), yet intense application-related burning pain remains a major barrier to its broader use. Optimizing procedural tolerability is particularly important in elderly patients who are vulnerable to systemic analgesic side effects. Thoracic paravertebral block (TPVB) provides segmental analgesia and may attenuate procedural pain during capsaicin patch application. Objective: To compare procedural tolerability and short-term analgesic outcomes of topical EMLA alone versus EMLA combined with TPVB before 8% capsaicin patch application in patients with thoracic PHN. Methods: This retrospective cohort study included adults with thoracic PHN treated with 8% capsaicin patches at Prince Fahd bin Sultan Hospital, Tabuk, Saudi Arabia, between January 2022 and February 2025. Patients received either EMLA alone ( Results: Baseline characteristics were comparable between groups. Patients who received TPVB demonstrated markedly superior procedural tolerability compared with those pretreated with EMLA alone. Intraprocedural pain was substantially reduced, with a markedly lower cumulative pain burden and no requirement for IV rescue in the TPVB group, whereas all EMLA patients required opioid rescue and reported intense burning pain during application. Post-procedural pain scores remained consistently lower in the TPVB group, accompanied by significant improvements in sleep quality and reduced reliance on oral analgesics during the following 48 h. Treatment acceptability was also substantially higher with TPVB, indicating a considerably more comfortable peri-procedural experience. Conclusion: TPVB combined with EMLA yielded profound improvements in procedural tolerability, early pain control, sleep quality, and patient acceptability during 8% capsaicin patch therapy for thoracic PHN, while markedly reducing opioid rescue needs. These findings support TPVB-assisted capsaicin therapy as a promising multimodal strategy deserving evaluation in prospective controlled trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.